We are live on
!
Find out more
GA
General Atlantic Portfolio holdings
AUM
$2.15B
1-Year Est. Return
35.02%
This Fund
S&P 500
This Quarter
Est. Return
+13.28%
1 Year Est. Return
+35.02%
3 Year Est. Return
+185.68%
5 Year Est. Return
+122.28%
10 Year Est. Return
+1,080.07%
AUM
$3.63B
AUM Growth
+$650M
(+22%)
Cap. Flow
+$380M
Cap. Flow
% of AUM
10.46%
Top 10 Holdings %
Top 10 Hldgs %
97.39%
Holding
18
New
3
Increased
1
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CHYM
Chime Financial
CHYM
|
+$633M |
| 2 |
BULL
Webull Corp
BULL
|
+$111M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$22.7M |
| 4 |
ALMS
Alumis Inc
ALMS
|
+$6.13M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alignment Healthcare
ALHC
|
+$274M |
| 2 |
XP
XP
|
+$70.8M |
| 3 |
Immunocore
IMCR
|
+$37.4M |
| 4 |
SLRN
ACELYRIN
SLRN
|
+$6.66M |
| 5 |
LOGC
ContextLogic
LOGC
|
+$4.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 49.33% |
| 2 | Healthcare | 34.36% |
| 3 | Financials | 14.2% |
| 4 | Consumer Staples | 2.11% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
dLocal
DLO
$4.28B
| $725M | 19.97% |
63,906,695
| – | – |
|
|
CHYM
2
Chime Financial
CHYM
$8.52B
| $663M | 18.26% |
+19,208,760
| New | +$633M |
|
|
3
Alignment Healthcare
ALHC
$3.81B
| $616M | 16.97% |
43,993,323
-17,000,000
| -28% | -$274M |
|
|
4
XP
XP
$8.41B
| $515M | 14.2% |
25,517,733
-4,100,000
| -14% | -$70.8M |
|
|
AKRO
5
DELISTED
Akero Therapeutics
AKRO
| $306M | 8.43% |
5,733,989
+500,000
| +10% | +$22.7M |
|
6
Alkami Technology
ALKT
$1.97B
| $291M | 8.01% |
9,645,318
| – | – |
|
7
Pharvaris
PHVS
$2.26B
| $133M | 3.65% |
7,531,252
| – | – |
|
|
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
| $127M | 3.51% |
9,681,818
| – | – |
|
|
BULL
9
Webull Corp
BULL
$3.77B
| $85.5M | 2.36% |
+7,148,051
| New | +$111M |
|
|
EWCZ
10
DELISTED
European Wax Center
EWCZ
| $73.8M | 2.03% |
13,110,492
| – | – |
|
11
Royalty Pharma
RPRX
$26.7B
| $54M | 1.49% |
1,500,000
| – | – |
|
12
Riskified
RSKD
$727M
| $26.6M | 0.73% |
5,324,998
| – | – |
|
|
ADAG
13
Adagene
ADAG
$242M
| $7.46M | 0.21% |
3,825,952
| – | – |
|
|
ALMS
14
Alumis Inc
ALMS
$3.32B
| $3.89M | 0.11% |
+1,297,530
| New | +$6.13M |
|
15
Grove Collaborative
GROV
$45.4M
| $2.85M | 0.08% |
2,474,859
| – | – |
|
|
16
Immunocore
IMCR
$1.68B
| – | – |
-1,261,684
| Closed | -$37.4M |
|
|
SLRN
17
DELISTED
ACELYRIN
SLRN
| – | – |
-2,695,327
| Closed | -$6.66M |
|
|
LOGC
18
DELISTED
ContextLogic
LOGC
| – | – |
-609,616
| Closed | -$4.26M |
|
Similar funds
NAAA
MA
SC
IIP
CI
AAP
RFP
TAL
General Atlantic's Q2 2025 Portfolio in Review
As of Q2 2025, General Atlantic held 18 positions worth $3.63B, up 22% from $2.98B the previous quarter. Its ten largest holdings account for 97% of the portfolio.
General Atlantic deployed $380M of net new capital in Q2 2025, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Chime Financial: 19,208,760 shares worth $663M.
By sector, the portfolio is most concentrated in Technology at 49% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Alignment Healthcare, an estimated $274M trimmed.
- General Atlantic's largest Q2 2025 buy was Chime Financial: 19,208,760 shares worth $663M.
- General Atlantic added most to Akero Therapeutics in Q2 2025, an estimated $22.7M increase.
- General Atlantic's biggest Q2 2025 reduction was Alignment Healthcare, cutting an estimated $274M.
- General Atlantic fully exited Immunocore in Q2 2025, selling an estimated $37.4M.
- General Atlantic's ten largest holdings make up 97% of its $3.63B portfolio in Q2 2025.
- General Atlantic opened 3 new positions and closed 3 in Q2 2025.
- General Atlantic's portfolio value rose 22% quarter-over-quarter to $3.63B.
Based on General Atlantic's 13F filing for Q2 2025, filed 14 Aug 2025.